BiotechTube
Seno Medical Instruments

Seno Medical Instruments

San Antonio, United States· Est.
senomedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $80M

Overview

Seno Medical Instruments, founded in 2005 and headquartered in San Antonio, Texas, is a commercial-stage diagnostics company. Its flagship product, the Imagio® Breast Imaging System, integrates opto-acoustic and ultrasound technology to help radiologists differentiate between benign and malignant breast lesions in a single, non-invasive exam. Enhanced by its native AI clinical decision support tool, SenoGram®, the system aims to address the inefficiencies, high costs, and patient anxiety associated with the current standard of care for breast cancer diagnosis. The company is focused on commercializing this technology to improve clinical outcomes and practice efficiency.

Oncology

Technology Platform

Opto-acoustic (OA) and ultrasound (US) fusion imaging platform. Uses laser light to generate functional data on blood oxygenation (via hemoglobin signature) combined with anatomical ultrasound, enhanced by a native AI clinical decision support tool (SenoGram®).

Funding History

4
Total raised:$80M
Debt$10M
Series C$30M
Series B$25M
Series A$15M

Opportunities

The massive scale of false-positive breast biopsies presents a multi-billion dollar cost burden and a significant patient anxiety problem, creating a strong value-based adoption argument.
The integration of its proprietary SenoGram® AI positions the company at the intersection of advanced imaging and digital health, a high-growth area.
Successful market penetration could make Seno an attractive strategic acquisition for a larger medical imaging company.

Risk Factors

Slow adoption due to clinician inertia and the challenge of integrating a new modality into standard radiology workflows poses a major commercial risk.
Securing adequate and favorable insurance reimbursement codes for the OA/US procedure is critical for financial viability.
The company faces competition from established imaging technologies and a growing array of AI-based software tools that aim to improve diagnostic accuracy on existing hardware.

Competitive Landscape

Seno competes in the breast imaging diagnostics space against entrenched modalities like diagnostic mammography, ultrasound, MRI, and newer technologies like contrast-enhanced mammography. It also faces competition from a proliferating number of AI software companies offering decision support tools for breast ultrasound and mammography. Imagio's differentiation is its hardware-based functional imaging capability, which is not directly replicated by pure software competitors.

More companies in Diagnostics & Precision Medicine →More companies in United States →